ID   UCLA # 1
AC   CVCL_M586
SY   UCLA#1
DR   Wikidata; Q54989623
RX   DOI=10.1007/0-306-46877-8_4;
RX   PubMed=9639523;
RX   PubMed=10936422;
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: B-cell; CL=CL_0000236.
DI   NCIt; C3242; Plasma cell myeloma
DI   ORDO; Orphanet_29073; Multiple myeloma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 10-09-24; Version: 11
//
RX   DOI=10.1007/0-306-46877-8_4;
RA   Jernberg-Wiklund H., Nilsson K.;
RT   "Multiple myeloma cell lines.";
RL   (In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).
//
RX   PubMed=9639523; DOI=10.1182/blood.V92.1.241.413k28_241_251;
RA   Xu F.-H., Sharma S., Gardner A., Tu Y.-P., Raitano A.B., Sawyers C.L.,
RA   Lichtenstein A.G.;
RT   "Interleukin-6-induced inhibition of multiple myeloma cell apoptosis:
RT   support for the hypothesis that protection is mediated via inhibition
RT   of the JNK/SAPK pathway.";
RL   Blood 92:241-251(1998).
//
RX   PubMed=10936422; DOI=10.1016/S0145-2126(99)00195-2;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   multiple myeloma and plasma cell leukemia.";
RL   Leuk. Res. 24:681-703(2000).
//